Showing posts with label Voyager. Show all posts
Showing posts with label Voyager. Show all posts

Monday, September 14, 2020

New Data Support The Idea That Neurocrine Biosciences Is Building A Credible Parkinson's Portfolio

I had previously expressed my concern that Neurocrine (NBIX) shares could remain weak given a lack of thesis-changing data catalysts on the horizon, and the shares have fallen another 17% since my last update. I see nothing wrong with the business, but the quality of the Ingrezza business is a known factor now and most of the company’s more exciting pipeline developments are still some distance away.

To that end, the recent presentations at the MDS Virtual Congress on the company’s NBIb-1817 Parkinson’s gene therapy program (licensed/partnered from Voyager (VYGR) and Ongentys (opicapone) are “nice to have” updates. I do believe that the lack of more robust positive data on the gene therapy program is a modest negative, though I also believe that the revenue potential of Ongentys remains somewhat underappreciated by investors.

I do continue to believe that Neurocrine is undervalued, but I also an ongoing risk that investors will ignore the name in favor of companies with more exciting near-term data updates.

 

Click here to continue: 

New Data Support The Idea That Neurocrine Biosciences Is Building A Credible Parkinson's Portfolio

Tuesday, April 30, 2019

Neurocrine Drifting, But The Total Package Is Still Appealing

Although Neurocrine Biosciences (NBIX) has a strong primary commercial asset in Ingrezza, a slower-building but still promising secondary asset partnered to AbbVie (ABBV) in Orlissa, and an improved pipeline, the reality is that the shares of biotechs in Neurocrine’s stage of life can flounder or drift for stretches of time. In the absence of new clinical data to get excited about, investors will instead fixate on short-term details or just get bored and move on, and I think that explains at least some of Neurocrine’s lackluster recent performance.

All in all, though, I still like this stock. I believe Ingrezza still has upside, and while Orlissa is taking longer to build than most investors would like, it’s still a good opportunity. Beyond that, opicapone may still be an underrated opportunity, and likewise with NBI-74788, and Neurocrine has some early-stage assets worth watching now, including its second VMAT-2 compound and its Voyager (VYGR) partnership.

Read more here:
Neurocrine Drifting, But The Total Package Is Still Appealing

Tuesday, February 26, 2019

Lundbeck Entering A Period Of Heightened Uncertainty

The next few years are going to seriously challenge the skills of H. Lundbeck’s (OTCPK:HLUYY) (LUN.KO) recently-hired CEO Deb Dunsire and head of R&D Johan Luthman, as the company has to contend with serious erosion in its mature portfolio, a very weak late-stage pipeline (not to mention risky early-stage assets), and the challenges that go with M&A and in-licensing. While Lundbeck does head into this difficult period with some strong drugs still early in their commercialization and a very clean balance sheet, investors need only look at Roche (OTCQX:RHHBY) to see how the market treats pharma companies with sluggish near-term EPS growth prospects.

Click here for more:
Lundbeck Entering A Period Of Heightened Uncertainty

Friday, February 8, 2019

Neurocrine Turns To Gene Therapy To Bolster Its Movement Disorder Franchise

I have been pretty consistently bullish on Neurocrine (NBIX) for a while, but one of my more frequent criticisms has been a relatively spartan pipeline. Where some biotechs will throw numerous compounds into trials in the hopes that something "sticks", Neurocrine has been far more selective in what it brings into human studies. While that almost certainly saves the company some money, it also leads to a thin pipeline and that weakness was brought back into focus recently with the failure of Ingrezza in a pivotal study of pediatric Tourette.

Neurocrine has taken a significant step to change that, with the announcement on January 29 of a partnership with Voyager (VYGR) for potentially four gene therapy programs in the CNS space. The most advanced program likely wouldn't be approved until 2024 (assuming the data are good enough), but Neurocrine could be acquiring some high-potential compounds in areas that are increasingly core to the company.

Follow this link for more:
Neurocrine Turns To Gene Therapy To Bolster Its Movement Disorder Franchise